Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aerie Pharmaceuticals, Inc.

https://aeriepharma.com/

Latest From Aerie Pharmaceuticals, Inc.

Aerie Misses Quick Path To Dry Eye Approval, But Is Still Moving Forward

AR-15512 missed the primary endpoints in a Phase IIb dry eye disease study that could have served as a pivotal trial, but Aerie’s drug hit enough signs and symptoms of the disease to justify a Phase III.

Clinical Trials Drug Approval Standards

Phesgo & Roclanda Among New Winners At EMA

The European Medicines Agency this week recommended that five new products be granted EU marketing approval.

Europe Approvals

Crunch Time For Aerie At EMA

Aerie is already exploring its pricing strategy for Roclanda as the European Medicines Agency this week decides whether the intraocular pressure treatment should be approved in Europe.

Ophthalmic Drug Review

ViiV Wins Fast-Track Review At EMA For HIV Therapy

A number of new products have been submitted for review at the European Medicines Agency. While marketing authorization applications from ViiV Healthcare and BioMarin Pharmaceutical are being fast-tracked, a submission from Incyte is not.

Europe Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Avizorex Pharma, S.L.
UsernamePublicRestriction

Register